HC Wainwright Reaffirms “Buy” Rating for Collegium Pharmaceutical (COLL)

Collegium Pharmaceutical (NASDAQ:COLL)‘s stock had its “buy” rating reiterated by stock analysts at HC Wainwright in a research report issued on Monday, September 17th.

Several other research analysts also recently commented on COLL. BidaskClub raised Collegium Pharmaceutical from a “hold” rating to a “buy” rating in a research note on Thursday, June 21st. Cantor Fitzgerald reissued a “buy” rating and set a $40.00 target price on shares of Collegium Pharmaceutical in a research note on Wednesday, June 20th. ValuEngine downgraded Collegium Pharmaceutical from a “strong-buy” rating to a “buy” rating in a research note on Monday, July 2nd. Janney Montgomery Scott set a $27.00 target price on Collegium Pharmaceutical and gave the stock a “buy” rating in a research note on Monday, August 6th. Finally, Piper Jaffray Companies set a $34.00 target price on Collegium Pharmaceutical and gave the stock a “buy” rating in a research note on Wednesday, July 11th. Three analysts have rated the stock with a hold rating and seven have given a buy rating to the stock. Collegium Pharmaceutical has an average rating of “Buy” and a consensus price target of $31.71.

COLL stock traded down $0.07 during midday trading on Monday, reaching $16.95. The company had a trading volume of 311,040 shares, compared to its average volume of 527,767. The company has a market cap of $489.69 million, a PE ratio of -6.86 and a beta of 0.43. Collegium Pharmaceutical has a 1-year low of $9.01 and a 1-year high of $29.90. The company has a quick ratio of 0.78, a current ratio of 0.82 and a debt-to-equity ratio of 3.94.

Collegium Pharmaceutical (NASDAQ:COLL) last posted its quarterly earnings results on Wednesday, August 8th. The specialty pharmaceutical company reported ($0.40) EPS for the quarter, beating the Zacks’ consensus estimate of ($0.42) by $0.02. The business had revenue of $73.10 million during the quarter, compared to the consensus estimate of $72.21 million. Collegium Pharmaceutical had a negative return on equity of 61.82% and a negative net margin of 39.10%. The company’s revenue for the quarter was up 1930.6% on a year-over-year basis. On average, analysts anticipate that Collegium Pharmaceutical will post -1.49 EPS for the current fiscal year.

A number of hedge funds have recently made changes to their positions in COLL. Millennium Management LLC boosted its holdings in Collegium Pharmaceutical by 1,171.8% in the second quarter. Millennium Management LLC now owns 361,035 shares of the specialty pharmaceutical company’s stock valued at $8,611,000 after acquiring an additional 332,647 shares during the last quarter. Summit Trail Advisors LLC boosted its holdings in Collegium Pharmaceutical by 2,221.9% in the first quarter. Summit Trail Advisors LLC now owns 332,708 shares of the specialty pharmaceutical company’s stock valued at $333,000 after acquiring an additional 318,379 shares during the last quarter. BlackRock Inc. boosted its holdings in Collegium Pharmaceutical by 13.8% in the second quarter. BlackRock Inc. now owns 2,252,273 shares of the specialty pharmaceutical company’s stock valued at $53,717,000 after acquiring an additional 272,302 shares during the last quarter. Macquarie Group Ltd. boosted its holdings in Collegium Pharmaceutical by 9.9% in the second quarter. Macquarie Group Ltd. now owns 2,588,356 shares of the specialty pharmaceutical company’s stock valued at $61,732,000 after acquiring an additional 233,598 shares during the last quarter. Finally, Northern Trust Corp boosted its holdings in Collegium Pharmaceutical by 78.5% in the second quarter. Northern Trust Corp now owns 526,499 shares of the specialty pharmaceutical company’s stock valued at $12,557,000 after acquiring an additional 231,463 shares during the last quarter. Institutional investors and hedge funds own 93.57% of the company’s stock.

Collegium Pharmaceutical Company Profile

Collegium Pharmaceutical, Inc, a specialty pharmaceutical company, develops and commercializes various products for patients suffering from pain. It provides DETERx platform technology that is designed to maintain the extended-release and safety profiles of highly abused drugs in the face of various methods of abuse and tampering, including chewing, crushing, and/or dissolving.

See Also: What is a stock buyback?

Analyst Recommendations for Collegium Pharmaceutical (NASDAQ:COLL)

Receive News & Ratings for Collegium Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Collegium Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply